艾滋病患者糖脂代谢的研究现状
Research Status of Glucolipid Metabolism in AIDS Patients
摘要: 抗反转录病毒治疗(Antiretroviral therapy, ART)的问世使越来越多的艾滋病病毒感染者的寿命得以延长，并在一定程度上大大降低了艾滋病相关疾病的发病率与死亡率，但随着艾滋病患者年龄的增加，各种慢性合并症(血脂异常、糖尿病、心血管疾病等)发病率越来越高。传统的风险因素、ART的应用及HIV导致的长期慢性炎症与免疫激活，使艾滋病患者的血脂、血糖代谢受到严重影响，由此发生的各种慢性合并症逐渐成为艾滋病患者死亡的主要原因。所以人们迫切需要了解艾滋病患者的血糖、血脂代谢特点，早期进行干预，改善患者的生存及预后。现就国内外艾滋病患者血脂、血糖代谢的研究现状加以综述。
Abstract: The advent of antiretroviral therapy (ART) prolongs the life of more and more HIV-infected people and greatly reduces the morbidity and mortality of AIDS-related diseases to a certain extent. How-ever, with the increase of age of AIDS patients, the incidence of various chronic complications (hy-pertension, diabetes, cardiovascular diseases, etc.) is increasing. Traditional risk factors, the appli-cation of ART and the long-term chronic inflammation and immune activation caused by HIV have seriously affected the metabolism of blood lipids and blood glucose in AIDS patients, and various chronic complications resulting from this have gradually become the main cause of death in AIDS patients. Therefore, it is urgent for people to understand the characteristics of glucose and lipid metabolism in AIDS patients, and to carry out early intervention to improve the survival and prog-nosis of patients. This paper reviews the research status of blood lipid and blood glucose metabo-lism in AIDS patients at home and abroad.
文章引用：李智慧, 沙敏, 吴健强. 艾滋病患者糖脂代谢的研究现状[J]. 临床医学进展, 2022, 12(8): 7307-7313. https://doi.org/10.12677/ACM.2022.1281055

参考文献

[1] UNAIDS (Joint United Nations Programme on HIV/AIDS) (2020) 2020 Global Aids Update—Seizing the Mo-ment—Tackling Entrenched Inequalities to End Epidemics. Joint United Nations Programme on HIV/AIDS, Geneva.
https://www.unaids.org/en/resources/documents/2020/globalaids-report
[2] Viard, J.P. (2014) Comorbidities in HIV Infection and Aging with HIV. La Revue du Praticien, 64, 1086-1090.
[3] 中华医学会感染病学分会艾滋病丙型肝炎学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南(2021年版) [J]. 协和医学杂志, 2022, 13(2): 203-226.
[4] Raposo, M.A., de Almeida Armiliato, G.N., Guimarães, N.S., et al. (2017) Metabolic Disorders and Car-diovascular Risk in People Living with HIV/AIDS without the Use of Antiretroviral Therapy. Revista da Sociedade Bra-sileira de Medicina Tropical, 50, 598-606. [Google Scholar] [CrossRef] [PubMed]
[5] Dai, L., Liu, A., Zhang, H., et al. (2019) Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study. Current HIV research, 17, 324-334. [Google Scholar] [CrossRef] 
[6] 石峰, 刘敏, 李明俊, 刘倩, 吴玉珊, 何坤. 含克力芝的抗逆转录病毒治疗方案对不同性别、不同年龄HIV感染人群血脂水平的影响研究[J]. 中国实用医药, 2021, 16(28): 155-158.
[7] 余旻虹, 赵艳伟, 杨慧, 宋晓璟, 何叶, 李佳倩, 等. 306例艾滋病患者的血脂异常情况及相关因素分析[J]. 中华实验和临床病毒学杂志, 2020(2): 122-127.
[8] Mizushima, D., Dung, N.T.H., Dung, N.T., Matsumoto, S., Tanuma, J., et al. (2020) Dyslipidemia and Cardiovascular Disease in Vietnamese People with HIV on Antiretroviral Therapy. Global Health & Medicine, 2, 39-42. [Google Scholar] [CrossRef] [PubMed]
[9] Kauppinen, K.J., Kivelä, P. and Sutinen, J. (2019) Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting. AIDS Patient Care and STDs, 33, 500-506. [Google Scholar] [CrossRef] [PubMed]
[10] Sun, L.-Q., Liu, J.-Y., He, Y., Zhou, Y., Xu, L.M., Zhang, L.K., et al. (2020) Evolution of Blood Lipids and Risk Factors of Dyslipidemia among People Living with Human Immunodefi-ciency Virus who Had Received First-Line Antiretroviral Regimens for 3 Years in Shenzhen. Chinese Medical Journal, 133, 2808-2815. [Google Scholar] [CrossRef] 
[11] Muche Belete, A., Seifu, D., Menon, M., Amogne, W., Shewa, A. and Adela Tefera, A (2021) Serum Lipid Profiles of Patients Taking Efavirenz-Based Antiretroviral Regimen Compared to Ritonavir-Boosted Atazanavir with an Optimized Background at Zewditu Memorial Hospital, Addis Ababa, Ethiopia. HIV/AIDS - Research and Palliative Care, 13, 217-227. [Google Scholar] [CrossRef] 
[12] Liu, D., Zhang, X., Kang, J., Gao, F., He, Y. and He, S. (2021) Gradual Increasing Dyslipidemia in Treatment-Naive Male Patients with Human Immunodeficiency Virus and Treated with Tenofovir plus Lamivudine plus Efavirenz for 3 Years. Diabetology & Metabolic Syndrome, 13, Article No. 135. [Google Scholar] [CrossRef] [PubMed]
[13] Tre-villyan, J.M., Wong, G., Puls, R., Petoumenos, K., Emery, S., Mellett, N.A., et al. (2018) Changes in Plasma Lipidome Following Initiation of Antiretroviral Therapy. PLOS ONE, 13, Article ID: e0202944. [Google Scholar] [CrossRef] [PubMed]
[14] Taramasso, L., Tatarelli, P., Ricci, E., Madeddu, G., Menzaghi, B., Squillace, N., et al. (2018) Improvement of Lipid Profile after Switching from Efavirenz or Ritonavir-Boosted Prote-ase Inhibitors to Rilpivirine or Once-Daily Integrase Inhibitors: Results from a Large Observational Cohort Study (SCOLTA). BMC Infectious Diseases, 18, Article No. 357. [Google Scholar] [CrossRef] [PubMed]
[15] The RESPOND Study Group (2021) Incidence of Dyslipidemia in People with HIV Who Are Treated with Integrase Inhibi-tors versus Other Antiretroviral Agents. AIDS, 35, 869-882. [Google Scholar] [CrossRef] 
[16] Tadesse, B.T., Foster, B.A., Chala, A., Chaka, T.E., Bi-zuayehu, T., Ayalew, F., et al. (2019) HIV and cART-Associated Dyslipidemia among HIV-Infected Children. Journal of Clinical Medicine, 8, Article No. 430. [Google Scholar] [CrossRef] [PubMed]
[17] Santiprabhob, J., Tanchaweng, S., Maturapat, S., Maleesatharn, A., Ler-mankul, W., Sricharoenchai, S., et al. (2017) Metabolic Disorders in HIV-Infected Adolescents Receiving Protease In-hibitors. BioMed Research International, 2017, Article ID: 7481597. [Google Scholar] [CrossRef] [PubMed]
[18] 马春涛, 王强, 张煜昆, 孟宪宇. 2009-2019年我国艾滋病免费抗病毒治疗药品构成分析[J]. 中国医药导报, 2021, 18(17): 157-160+168+封4.
[19] Nansseu, J.R., Bigna, J.J., Kaze, A.D. and Noubiap, J.J. (2018) Incidence and Risk Factors for Prediabetes and Diabetes Mellitus among HIV-Infected Adults on Antiretroviral Therapy: A Systematic Re-view and Meta-analysis. Epidemiology, 29, 431-441. [Google Scholar] [CrossRef] 
[20] Kumar, S. and Samaras, K. (2018) The Impact of Weight Gain during HIV Treatment on Risk of Pre-Diabetes, Diabetes Mellitus, Cardiovascular Disease, and Mortality. Frontiers in Endocrinology, 9, Article No. 705. [Google Scholar] [CrossRef] [PubMed]
[21] Nolan, N.S., Adamson, S., Reeds, D. and O’Halloran, J.A. (2021) Bictegravir-Based Antiretroviral Therapy-Associated Accelerated Hyperglycemia and Diabetes Mellitus. Open Forum Infectious Diseases, 8, ofab077. [Google Scholar] [CrossRef] [PubMed]
[22] Paengsai, N., Jourdain, G., Salvadori, N., Tantraworasin, A., Mary, J.Y., Cressey, T.R., et al. (2019) Recommended First-Line Antiretroviral Therapy Regimens and Risk of Diabetes Mellitus in HIV-Infected Adults in Resource-Limited Settings. Open Forum Infectious Diseases, 6, ofz298. [Google Scholar] [CrossRef] [PubMed]
[23] Echecopar-Sabogal, J., D’Angelo-Piaggio, L., Chanamé-Baca, D.M. and Ugarte-Gil, C. (2018) Association between the Use of Protease Inhibitors in Highly Active Antiretroviral Therapy and Incidence of Diabetes Mellitus and/or Metabolic Syndrome in HIV-Infected Patients: A Systematic Review and Me-ta-Analysis. International Journal of STD & AIDS, 29, 443-452. [Google Scholar] [CrossRef] [PubMed]
[24] Tadesse, W.T., Adankie, B.T., Shibeshi, W., Amogne, W., Aklillu, E. and Engidawork, E (2022) Prevalence and Predictors of Glucose Metabolism Disorders among People Living with HIV on Combination Antiretroviral Therapy. PLOS ONE, 17, e0262604. [Google Scholar] [CrossRef] [PubMed]
[25] Rebeiro, P.F., Jenkins, C.A., Bian, A., Lake, J.E., Bourgi, K., Moore, R.D., et al. (2021) Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships with Integrase In-hibitor-Based Initial Antiretroviral Therapy among Persons with Human Immunodeficiency Virus in the United States and Canada. Clinical Infectious Diseases, 73, e2234-e2242. https://pubmed.ncbi.nlm.nih.gov/32936919 [Google Scholar] [CrossRef] [PubMed]
[26] Shah, S., Hindley, L. and Hill, A. (2021) Are New Antiretroviral Treatments Increasing the Risk of Weight Gain? Drugs, 81, 299-315. [Google Scholar] [CrossRef] [PubMed]
[27] Shah, S. and Hill, A. (2021) Risks of Metabolic Syndrome and Diabetes with Integrase Inhibitor-Based Therapy. Current Opinion in Infectious Diseases, 34, 16-24. [Google Scholar] [CrossRef] 
[28] Bourgi, K., Jenkins, C.A., Rebeiro, P.F., Shepherd, B.E., Palella, F., Moore, R.D., et al. (2020) Weight Gain among Treatment-Naïve Persons with HIV Starting Integrase Inhibi-tors Compared to Non-Nucleoside Reverse Transcriptase Inhibitors or Protease Inhibitors in a Large Observational Co-hort in the United States and Canada. Journal of the International AIDS Society, 23, Article ID: e25484. [Google Scholar] [CrossRef] [PubMed]
[29] Tiozzo, E., Rodriguez, A., Konefal, J., Farkas, G.J., Maher, J.L. and Lewis, J.E. (2021) The Relationship between HIV Duration, Insulin Resistance and Diabetes Risk. International Journal of En-vironmental Research and Public Health, 18, Article No. 3926. [Google Scholar] [CrossRef] [PubMed]
[30] Duguma, F., Gebisa, W., Mamo, A., Tamiru, D. and Woyesa, S. (2020) Diabetes Mellitus and Associated Factors among Adult HIV Patients on Highly Active Anti-Retroviral Treatment. HIV/AIDS - Research and Palliative Care, 12, 657-665. [Google Scholar] [CrossRef] 
[31] Han, W.M., Jiamsakul, A., Kiertiburanakul, S., Ng, O.T., Sim, B., Sun, L.P., et al. (2019) Diabetes Mellitus Burden among People Living with HIV from the Asia-Pacific Region. Journal of the International AIDS Society, 22, Article ID: e25236. [Google Scholar] [CrossRef] [PubMed]
[32] McMahon, C.N., Petoumenos, K., Hesse, K., Carr, A., Cooper, D.A. and Samaras, K. (2018) High Rates of Incident Diabetes and Prediabetes Are Evident in Men with Treated HIV Followed for 11 Years. AIDS, 32, 451-459. [Google Scholar] [CrossRef] 
[33] 何小清, 沈银忠, 张仁芳, 刘莉, 王江蓉, 陈军. 未启动抗反转录病毒治疗的人类免疫缺陷病毒/艾滋病患者发生心血管疾病的风险评估[J]. 中华传染病杂志, 2020, 38(10): 640-645.
[34] Ballocca, F., D’Ascenzo, F., Gili, S., Grosso Marra, W. and Gaita, F. (2017) Cardiovascular Disease in Patients with HIV. Trends in Cardiovascular Medicine, 27, 558-563. [Google Scholar] [CrossRef] [PubMed]
[35] Shah A S V, Stelzle, D., Lee, K.K., Beck, E.J., Alam, S., Clifford, S., et al. (2018) Global Burden of Atherosclerotic Cardiovascular Disease in People Living with HIV: Systematic Review and Meta-Analysis. Circulation, 138, 1100-1112. [Google Scholar] [CrossRef] 
[36] Guo, F., Hsieh, E., Lyu, W., Han, Y., Xie, J., Li, Y., et al. (2017) Cardiovascular Disease Risk among Chinese Antiretroviral-Naïve Adults with Advanced HIV Disease. BMC Infectious Diseases, 17, Article No. 287. [Google Scholar] [CrossRef] [PubMed]
[37] Pierre, S., Seo, G., Rivera, V.R., Walsh, K.F., Victor, J.J., Charles, B., et al. (2019) Prevalence of Hypertension and Cardiovascular Risk Factors among Long-Term AIDS Survi-vors: A Report from the Field. The Journal of Clinical Hypertension, 21, 1558-1566. [Google Scholar] [CrossRef] [PubMed]
[38] Ryom, L., Lundgren, J.D., El-Sadr, W., Reiss, P., Kirk, O., Law, M., et al. (2018) Cardiovascular Disease and Use of Contemporary Protease Inhibitors: The D:A:D International Prospective Mul-ticohort Study. The Lancet. HIV, 5, e291-e300. [Google Scholar] [CrossRef] 
[39] Losina, E., Hyle, E.P., Borre, E.D., Linas, B.P., Sax, P.E., Weinstein, M.C., et al. (2017) Projecting 10-Year, 20-Year, and Lifetime Risks of Cardiovascular Disease in Persons Living with Human Immunodeficiency Virus in the United States. Clinical Infectious Diseases, 65, 1266-1271. [Google Scholar] [CrossRef] [PubMed]
[40] Maggi, P., Di Biagio, A., Rusconi, S., Cicalini, S., d’Abbraccio, M., d’Ettorre, G., et al. (2017) Cardiovascular Risk and Dyslipidemia among Persons Living with HIV: A Review. BMC Infectious Diseases, 17, Article No. 551. [Google Scholar] [CrossRef] [PubMed]

为你推荐